Schrodinger, Inc.

SDGR

Generative AIPrecision medicineBiotech & pharmaceuticals

$27.28vs prev close▲+0.89(+3.37%)

$10.9552W Range$33.78

72% from low

+7.97 (+41.90%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.44%

1M +0.09%p

Holding ETFs

1 ETFs

ARKG

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +1.3% · Market value +59.5% · Weight +0.09%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.08.14	BUY	ARKG	4,717	$17.59	$83.0K
26.08.13	BUY	ARKG	28,179	$18.46	$520.2K
26.08.12	BUY	ARKG	9,356	$18.63	$174.3K
26.08.11	BUY	ARKG	16,060	$18.65	$299.5K
26.08.10	BUY	ARKG	1,044	$18.77	$19.6K
26.08.07	BUY	ARKG	29,970	$18.16	$544.3K
26.08.06	BUY	ARKG	48,584	$17.81	$865.3K
25.12.18	BUY	ARKG	103,106	$17.20	$1.8M
25.12.15	BUY	ARKG	14,043	$18.21	$255.7K
25.12.12	BUY	ARKG	54,917	$18.05	$991.3K
25.12.11	BUY	ARKG	36,554	$18.13	$662.7K
25.04.30	SELL	ARKG	5,721	$25.63	$146.6K
25.04.29	SELL	ARKG	67,053	$25.78	$1.7M
25.04.28	SELL	ARKG	61,893	$25.75	$1.6M
24.11.14	BUY	ARKG	11,803	$20.37	$240.4K

08.14BUY

4,717

ARKGClose$17.59Est. total$83.0K

08.13BUY

28,179

ARKGClose$18.46Est. total$520.2K

08.12BUY

9,356

ARKGClose$18.63Est. total$174.3K

08.11BUY

16,060

ARKGClose$18.65Est. total$299.5K

08.10BUY

1,044

ARKGClose$18.77Est. total$19.6K

08.07BUY

29,970

ARKGClose$18.16Est. total$544.3K

08.06BUY

48,584

ARKGClose$17.81Est. total$865.3K

12.18BUY

103,106

ARKGClose$17.20Est. total$1.8M

12.15BUY

14,043

ARKGClose$18.21Est. total$255.7K

12.12BUY

54,917

ARKGClose$18.05Est. total$991.3K

12.11BUY

36,554

ARKGClose$18.13Est. total$662.7K

04.30SELL

5,721

ARKGClose$25.63Est. total$146.6K

04.29SELL

67,053

ARKGClose$25.78Est. total$1.7M

04.28SELL

61,893

ARKGClose$25.75Est. total$1.6M

11.14BUY

11,803

ARKGClose$20.37Est. total$240.4K

1 / 4

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

2,329,349

Portfolio Weight

0.44%

in ETF 3.11%

Est. Value

$76M

30D Net

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

None

Buy

Hold

Analyst Targets

avg.

$21.43

vs Current ▼ -21.4% downside

Current$27.28

Low ~ High$17.00 ~ $30.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Morgan Stanley

Equal-Weight

$17.00

-37.68%

—

Maintain

2026-05-14

Keybanc

Overweight

$20.00

-26.69%

—

Maintain

2026-04-08

UBS

Neutral

$13.00

-52.35%

—

Maintain

2026-03-17

TD Cowen

Buy

$24.00

-12.02%

—

Maintain

2026-01-08

Keybanc

Overweight

$25.00

-8.36%

—

Maintain

2026-01-08

1 / 4

Avg Target

$21.43

vs Current ▼ -21.4% downside

None

7 analysts

Buy 5Hold 2

Low $17.00

Current $27.28

High $30.00

Firm	Position	Target	Upside	Close	Action	Date
Morgan Stanley	Equal-Weight	$17.00	-37.68%	—	Maintain	26.05.14
Keybanc	Overweight	$20.00	-26.69%	—	Maintain	26.04.08
UBS	Neutral	$13.00	-52.35%	—	Maintain	26.03.17
TD Cowen	Buy	$24.00	-12.02%	—	Maintain	26.01.08
Keybanc	Overweight	$25.00	-8.36%	—	Maintain	26.01.08

1 / 4

Price Information

Previous Close$26.39

Open$26.61

Day Range$26.37 - $28.16

52-Week Range$10.95 - $33.78

1-Year Change38.48%

Trading Volume

Volume2,076,875

Avg Volume (3mo)1,793,896

Valuation

Market Cap2.0B

Book Value$4.51

Shares Outstanding65,641,435

Financials

Revenue (TTM)259.0M

Net Income-54,335,000

EPS$-0.74

EBITDA-147,579,008

Profitability

P/E Ratio-

P/B Ratio6.04

Return on Equity (ROE)-16.17%

Return on Assets (ROA)-14.44%

Profit Margin-20.98%

EV/EBITDA-11.76

Beta1.62

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)40.19

Company Overview

Schrödinger, Inc. develops a physics-based computational platform for discovering new molecules in drug development and materials science. The company offers software solutions and also engages in drug discovery through internal programs and collaborations, positioning itself as a key player in transforming molecular discovery.

P/B

6.04

High valuation

ROE

-16.2%

Net loss

Beta

1.62

High volatility

RSI(14)

40.2

Neutral zone

AI-generated summary. Not investment advice.

Schrodinger, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks